MOL 74968 (9-[2-methylidene-3-(phosphonomethoxy)-propyl]guanine), a novel acyclonucleotide derivative of guanine, inhibited human immunodeficiency virus type 1 (HIV-1) replication in vitro with activity comparable to that of adefovir (PMEA; 9-(2-phosphonomethoxyethyl)adenine). MOL 74968 was investigated in combination with two licensed nucleoside analogues, zidovudine and didanosine, using a cell viability assay, and drug interactions were evaluated by the isobologram technique, by calculating combination indices and by the MacSynergyTM program. Inhibition of HIV-1 replication was only additive in both cases. MOL 74968 had equivalent antiviral activity against strains of HIV-1 HxB2 engineered to have mutations which conferred resistance to the nucleoside analogues lamivudine, didanosine and zidovudine and the non-nucleoside inhibitor of reverse transcriptase (RT) nevi rapine, as against the wild type strain. Continued passage of HIV-1 R F in C8166 cells in the presence of MOL 74968 for 5 months (30 passages) failed to select drug resistant mutants. Continued passage of virus in the presence of the same concentration of adefovir for the same length of time selected a virus in a single culture, which was 3-fold resistant to adefovir and cross-resistant to MOL 74968. Genotypic characterization of this virus revealed a lysine to arginine exchange (AAA to AGA) at position 65 in the RT gene. This virus was not cross-resistant to either zidovudine or nevirapine but
Introduction
MDL 74968 (9-[2-methylidene-3-(phosphonomethoxy)-propyl]guanine), a novel acyclonucleotide derivative of guanine, was recently reported to have activity against the replication of human immunodeficiency virus type 1 (HIV-1) in vitro . The antiviral activity was comparable with that of another acyclic nucleoside phosphonate derivative, adefovir (PMEA; 9-(2-phosphonomethoxyethyl)adenine) (De Clercq et al., 1987; Pauwels et al., 1988b; Balzarini et el., 1991; De Clercq, 1991 ): see Fig. 1 for structures of MDL 74968 and adefovir. Adefovir is a compound which has shown potent antiviral efficacy in animal models of retrovirus infections (Gangemi et al., 1989; Egberink et al., 1990; Tsai et al., 1994; Tsai et al., 1995) , and a prodrug bis-POM-PMEA is currently undergoing clinical trials in patients with the acquired immunodeficiency syndrome (AIDS) (BarditchCrovo et et., 1995) . The cytotoxicity of MDL 74968 for T cells was less than that of adefovir, which provided a superior selective index . Most recently, MDL 74968 has been shown to have good invitro antiviral activity against a range of clinical isolates of HIV-1 and HIV-2 in human peripheral blood mononuclear cells and in-vivo efficacy against HIV-1 using the hu·PBL-SCID:beige mouse model of infection . These results indicate that MDL 74968 may have therapeutic value.
One of the major problems encountered with the clinical use of antiviral agents targeted towards the reverse transcriptase (RT) of HIV has been the rapid emergence of drug resistance Richman, 1993) . As a result, the clinical benefit afforded by these compounds may deteriorate with time (O'Aquila et al., 1995; . Potentially, one way to prevent or at least delay the selection of drug resistant mutants is to use compounds in combination. The concurrent use of different drugs in this way may also generate synergistic antiviral activity and would minimize potential side-effects as lower concentrations of each drug could be administered. Recently it has become clear that the nucleoside RT inhibitor zidovudine (AZT), used in combination with the other licensed nucleoside analogues lamivudine (3TC) , didanosine (ddl) or zalcitabine (ddC) (Choo, 1995) , is better than zidovudine alone when used to treat HIV-infected patients. In addition the use of lamivudine in combination with zidovudine appears to suppress resistance to zidovudine . The effect of MOL 74968 in combination with two of these licensed compounds, zidovudine and didanosine, was investigated in order to identify any synergistic or antagonistic interactions.
The inhibitory activity of MOL 74968 and adefovir against genotypically characterized viruses with reduced sensitivity to a range of RT inhibitors, compared with the wild type strain, was also investigated to identify any patterns of cross-resistance. Finally, the ability of MOL 74968 to select for drug resistant mutants in cell culture was studied in comparison with adefovir, zidovudine and the non-nucleoside RT inhibitor nevirapine, and the emergent virus populations genotypically and phenotypically characterized.
Results

Antiviral activity of MDL 74968 alone and in combination
In C8166 or MT-4 cells infected with HIV-1RF or HIV-1HXB2, MOL 74968 had comparable antiviral activity to adefovir and didanosine, but was less active than the nucleoside RT inhibitors zidovudine, zalcitabine, and lamivudine and the non-nucleoside RT inhibitor, nevirap-NH2 <=6
o~PO(OH)'
Adefovir: PMEA ine (Table 1) . Similar antiviral activity was seen irrespective of virus strain or cell type used, in contrast to zidovudine, which was ",100-fold less active and also less toxic for C8166 cells compared with MT-4 cells.
When MOL 74968 was studied in combination with either zidovudine or didanosine, the calculated combination indices were all <1 (Table 2 ) and the isobolograms were slightly concave in shape (Fig. 2) , indicative of a marginal synergistic effect with both combinations. Statistical analysis of the raw data using the MacSynergyTM program revealed, however, that this synergy was not significant, and that MOL 74968 was only additive in combination with either zidovudine or didanosine. No cytotoxicity was evident when MOL 74968 (100IlM) was used in conjunction with either zidovudine (311M) or didanosine (100IlM), the highest concentrations used in these combination assays. 
Polymerase chain reaction/sequencing of RT region
The proviral nucleic acid sequence of the RT gene of the wild type HIV-1RF strain used in this study differed slightly
Selection of drug resistant mutants
HIV-1 RF was continuously passaged in parallel cultures of C8166 cells at increasing concentrations of either MOL 74968, adefovir, zidovudine or nevirapine, up to a maximum concentration of 128J..l.M. For each inhibitor, at least six different long-term cultures were ongoing during the course of the experiment which was continued for 30 passages over a period of 5-6 months. Virus that showed>1O-fold resistance to nevirapine was first selected in one culture after only eight passages and was subsequently selected in the other cultures. In contrast, virus with resistance to zidovudine was first selected after 17 passages, and virus resistant to either MOL 74968 or adefovir did not appear to emerge even after 28 passages. After 30 passages there was only one culture in which virus, grown continuously in adefovir, showed a 3-fold reduced level of sensitivity to this drug. In all other longterm cultures, in the presence of either of the acyclic nucleoside phosphonate derivatives, HIV-1RF remained sensitive to both adefovir or MOL 74968. acid change 74 V) and lamivudine (amino acid change 184 V) (Table 3 ). Both acyclic nucleoside phosphonate derivatives also had equivalent inhibitory activity against a virus engineered to have triple drug resistance to zidovudine, didanosine, and nevirapine (amino acid changes 41L; 74V; 106A and 215Y) as againstthe wild type (Table 3) . For viruses selected for resistance to nevirapine, nucleotide exchanges were identified in codons 106 (GTA to ATA or GCA; valine to isoleucine or alanine), 188 (TAT to TGT; tyrosine to cysteine), and 196 (GGG to AGG, glycine to arginine). For viruses resistant to zidovudine, nucleotide exchanges were identified in codons 41 (ATG to CTG; methionine to leucine), 70 (AAA to AGA; lysine to arginine), 103 (AGG to AAG; arginine to lysine) and 220 (AAA to AAG; conservative) (see Table 4 ). Three viruses which had been passaged extensively in the presence of MOL 74968 were sequenced, and in agreement with a lack of phenotypic resistance, no mutations were identified. When three viruses, which had been passaged up to 30 times in the presence of adefovir were sequenced, a single nucleotide exchange was identified in one virus population. The mutation was an AAA change to AGA at codon 65 (lysine to arginine change) and resulted in phenotypic resistance in this virus population alone. (Bridges et aI., 1995) . It is concluded from this collection of observations on antiviral activities coupled to favourable cytotoxicity and early toxicology, that MOL 74968 deserves recognition as a preclinical drug candidate. This current study now adds further information to support this premise. Recombinant viruses carrying mutations, which are known to occur in vivo after treatment of patients with either zidovudine, didanosine, lamivudine or nevirapine (Mellors et ei., 1995) , remained sensitive to either MOL 74968 or adefovir. This suggested that this class of compound could be particularly useful in patients harbouring such drug resistant strains of HIV. These results are in agreement with a previous study which indicated that viruses isolated from HIV-infected patients treated with zidovudine and exhibiting intermediate resistance to this compound, were still sensitive to adefovir (Gong et a/., 1994) . Although an additive effect was only observed when MOL 74968 was used in combination with the RT inhibitors zidovudine or didanosine, there was no antagonism and this compound could also be useful in two-or three-way drug combination regimens, to prevent or delay the emergence of drug resistant virus populations.
Perhaps the most important observation in this study was that virus resistant to the inhibitory effects of MOL 74968 or adefovir was not rapidly selected for in cell culture, in contrast to nevirapine and zidovudine. Mutations associated with nevirapine resistance were V106A Y188C and G196R. The V106A amino acid exchange hab een previously selected both in cell culture and in nevirapine-treated patients, whereas the Y188C substitutlon has only been previously reported in vivo (Richman, 1993; Richman et a/., 1994) : both of these codon changes have been confirmed by site-directed mutagenesis to confer resistance to nevirapine. The G196R substitution observed in the highly resistant virus HIV-1RF461 in combination with the V1061 and Y188C amino acid exchanges, has not been previously reported and mayor may not be significant.
It was surprising that viruses selected as resistant to zidovudine did not have a threonine to tyrosine or phenylalanine codon substitution at position 215, as this is the mutation most commonly associated with zidovudineresistance. However, both the M41Land K70R amino and in vivo were observed (Larder and Kemp, 1989 The sequenced viruses described above were screened for drug sensitivity against zidovudine, nevirapine, adefovir and MOL 74968, in order to determine accurately the degree of resistance and to establish whether or not they displayed cross-resistance to other RT inhibitors. The results are shown in Table 4 . Viruses selected in the presence of nevirapine showed high level resistance to this drug, but were still sensitive to zidovudine, adefovir and MOL 74968. Similarly, viruses selected in the presence of zidovudine only showed resistance to this compound. Viruses passaged up to 30 times in MOL 74968 or adefovir, for which no mutations had been identified, were sensitive to all of the RT inhibitors. The one virus (HIV-1RF554) selected after growth in the presence of adefovir in which a mutation (K65R) was identified, showed crossresistance to MOL 74968, but remained sensitive to nevirapine and zidovudine. This virus (HIV-1RF554), was also investigated for cross-resistance to didanosine, zalcitabine and lamivudine with the degree of resistance to both adefovir and MOL 74968 more accurately determined (Table 5 ). The acyclic nucleoside phosphonate derivatives were between 3-and 4-fold resistant with potential low level resistance in evidence for both didanosine and zalcitabine (2-fold and 2.3-fold, respectively). The exchange of arginine to lysine at codon 65 in HIV-1RF554, however, produced a 28-fold lower sensitivity to lamivudine than wild type.
sion to the consensus sequence in the absence of any other amino acid changes appeared to confer a 4-fold level of resistance to zidovudine, a phenomenon which would be interesting to confirm by site-directed mutagenesis. This R103K codon exchange however, was generally seen in conjunction with the more important M41 Land K70R amino acid exchanges. In a parallel study (results not shown), it was readily possible to select virus with reduced sensitivity to the proteinase inhibitor saquinavir after ",20 passages, which had amino acid substitutions in positions 48 and 90 as previously reported (Mellors et al., 1995) . In contrast, even after 30 passages in the presence of concentrations of MOL 74968 up to 100J..LM, virus remained sensitive to this compound when screened by the MTT assay.
In agreement with Gong et al. (1994) , similar difficulties were experienced selecting for viruses resistant to adefovir, although a single virus population was recovered after 30 passages which had 3.7-fold reduced sensitivity to adefovir. Interestingly, the single nucleotide substitution (AAA to AGA) which produced a lysine to arginine change at amino acid site 65, had been previously reported in variants selected for in-vitro after growth of infected cells in the presence of zalcitabine (Gu et al., 1994; Zhang et al., 1994) . Recombinant virus with this mutation possessed greater than 10-fold resistance against zalcitabine, and cross-resistance of 20-fold against lamivudine and 3-fold against didanosine. This mutation was also found in patients on long-term zalcitabine or didanosine therapy (Gu et al., 1994) . Consistent with our findings, it has recently been reported that HIV-1 with such a K65R mutation was about 12-15-fold resistant to adefovir, and that mutated recombinant K65R reverse transcriptase was resistant to PMEA-diphosphate, the active metabolite of adefovir, in a cell-free enzyme assay (Gu et al., 1995) . Coincidentally, when the K65R mutant virus population was screened for cross-resistance to other RT inhibitors, high level resistance to lamivudine (28-fold) and some resistance to both zalcitabine (2.3-fold) and didanosine (2-fold) was also observed. This virus also showed a 3-fold level of cross-resistance to MOL 74968, but remained sensitive to zidovudine. Overall, these results suggest that MOL 74968 or adefovir would be best used in combination with zidovudine and/or drugs with alternative mechanisms of action, rather than lamivudine, zalcitabine or didanosine, as it is likely that virus with multiple drug resistance would emerge.
Materials and Experimental Procedures
Compounds MOL 74968 and adefovir were synthesized as previously described (Holy and Rosenberg,1987; Casara et el., 1995) . 2',3"-Dideoxyinosine (ddl; didanosine) and 2',3'-dideoxycytidine (ddC; zalcitabine) were purchased from the Sigma Chemical Co Ltd, Dorset, UK. (-)-P-L-2',3'-Dideoxy-B"-thiacytidine (3TC; lamivudine) and 3'-azido-3"-deoxythymidine (AZT; zidovudine)were provided by Glaxo Wellcome, Stevenage, UK and nevirapine (BI-RG-587) by Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT, USA.
Cells and viruses
The T cell lines MT-4 and C8166 and the virus strains HIV-1 RF and HIV-1 HxB2 were obtained from Dr Harvey Holmes, MRC AIDS Directed Programme (MRC ADP) Reagent Project, NIBSC, Potters Bar, UK. Cells were cultured in RPMI 1640 (Gibco BRL, Middlesex, UK) supplementedwith 10% (v/v) fetal calf serum, 290/1g mL-1 glutamine, 100U mL-1 penicillin and 50/1g mL-1 streptomycin. The drug resistant strains of HIV-1HXB2 were also obtained from the MRC ADP Reagent Project donated by Dr Brendan Larder and Dr Sharon Kemp (Glaxo Wellcome). HIV-1HxB2ADP141 was engineered by site directed mutagenesis to have phenotypic resistance to zidovudine (mutations: 67N; 70R; 215F and 219Q) and similarly, HIV-1HXB2ADP145 was resistant to lamivudine (mutation: 184 V), HIV-1HxB2ADP144 was resistant to didanosine (mutation: 74 V), and HIV-1HxB2ADP146 resistant to zidovudine, didanosine and nevirapine (mutations:41L; 74V; 106A and 215Y).
Antiviral assays
All antiviral assays were carried out using the tetrazolium reduction (MTT) cell viability assay as previously described (Pauwels et al., 1988a) .
Drug combination assays
The MTT cell viability assay described above was adapted for analysing the anti-HIV effects of MDL 74968 in combination with zidovudine and didanosine. Assays were carried out essentially as described elsewhere . Briefly, chequerboards of the different combinations were generated in 96-well cell culture plates, by diluting one drug horizontally and the other vertically across the plates. The viability of HIV-1 RF infected MT-4 cells was assessed after 6 days, using MTT, and the plates were read at 540 nm. Raw ASCII data from the plate readerwere captured by Ultroterm software and further processed by Microsoft Excel, with minimal user intervention. A series of linked Excel macros was written to calculate the means and standard deviations of O.D. values and then plot dose-response graphs. From these graphs the 50% inhibitory concentrations (IC 50 s) for each drug at a fixed concentration of the other, as well as for each drug alone, were determined.These IC 50 values were used to construct isobolograms and to calculate a combination index (C.I.) using the followinq formula
as previously described (Chou and Talalay, 1984; Suhnel, 1990) . In this formula (DX)A = the IC 50 of drug A alone, (DX)B = the IC 50 of drug B alone, and (D)A or (D)B = the concentrations of drugs A and B in combination giving 50% protection of the cells. The constant a= 1 for mutually non-exclusiveagents and 0:= 0 for mutually exclusive agents. A C.1. value of < 1 was indicative of synergism and a C.1. value of > 1 antagonism. The raw data was also statistically analysed using the MacSynergyTM program which uses the Prichard and Shipman method (Prichard and Shipman, 1990) .
Selection of drug resistant mutants
The wild type HIV-1 strain RF was cultured in C8166 cells in the presence of eight different concentrations (doubling dilutions) of either MOL 74968 (11lM -128IlM), adefovir (11lM -128IlM), nevirapine (0.1IlM -12.8IlM) or zidovudine (0.5IlM -64IlM), using 24-well cell culture plates. Every 7 days, the cell free culture fluids from wells containing the highest concentration of RT inhibitor showing cytopathic effect were passaged into fresh C8166 cells and again cultured in the presence of the different concentrations of the appropriate inhibitor. The maximum concentration of MOL 74968 and adefovir used was 1281lM because at concentrations above this adefovir started to show signs of cytotoxicity. Periodically, virus growing at the highest concentrations of drug was screened for sensitivity by the MTT assay using C8166 cells, after being grown once in the absence of inhibitor. In the case of MOL 74968 and adefovir, where no resistant virus appeared to be selected, virus was passaged a maximum of 30 times and the RT gene then sequenced to identify any genotypic changes.
Polymerase chain reaction and sequencing
Once drug resistant virus had been selected and phenotypically characterized, DNA was purified from drug-treated virusinfected cultures using the Qiagen Blood and Cell Culture DNA Kit (Qiagen Ltd, Dorking, Surrey, UK) and a gene fragment encompassing the RT active site amplified using the Polymerase Chain Reaction (PCR). Primers used for PCR amplification were M7962 (5' GTT GCA CTT TAA ATT TTC CCA TTA G 3') and N2204 (5' TAT AGG CTG TAC TGT CCA TTT ATC A 3') and were synthesized by Oswel DNA Services (University of Southampton, UK). Cycle conditions were as follows: initial denaturation (2 min at 95°G) followed by 35 cycles (1 min at 95°C, 2 min at 55°C and 3 min at 72°G) and finally 7 min at 68°C. Amplified DNA was analysed for correct fragment size by agarose gel electrophoresis and purified using QIAquick Spin PCR Purification Kit (Qiagen Ltd). Sequencing was performed on two independently generated PCR amplifications, using the following primers M7027 (5' CTG TAC CAG TAA AAT TAA AGC CAG G 3'), AA105 (5' TGA AAA TCC ATA CAA TAC 3'), G0831 (5' GAA CTT AAT AAG AGAACT CAA GAC 3'), AA107 (5' ATA CTG CAT TTA CCA TAC 3') and AA106 (5' AGA AAT AGG GCA GCA TAG A 3'), [ 3 5SjdATP, and the Sequenase PCR Product Sequencing Kit (Amersham International, Bucks., UK), according to the manufacturer's recommendations.
